Cytoreductive Surgery Clinical Trial
Official title:
Diagnostic Performance of PET/MRI Versus Standard of Care Imaging (PET/CT and/or CT and/or PET) in Preoperative Women With Presumed Early-stage High Grade Endometrial Carcinoma
NCT number | NCT05390021 |
Other study ID # | 22-112 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | March 30, 2024 |
Est. completion date | February 1, 2026 |
Verified date | April 2024 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial cancer. The name of the intervention involved in this study is: Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 1, 2026 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Women aged 18-85 years old with an endometrial biopsy-confirmed diagnosis of either grade 3 endometrioid, serous, carcinosarcoma, undifferentiated or mixed cell carcinoma - Must have presumed stage I disease, i.e., no symptoms suggesting disease outside of the uterus (weight loss, early satiety, bloating, changes in bowel movement, etc.) - Planning to undergo cytoreductive surgery with a Gynecologic oncologist employed by Massachusetts General Hospital - No previous history of chronic severe renal insufficiency and a glomerular filtration rate of >30 mL/min/1.73m2. If the patient has a history of acute renal failure but their GFR as recovered to above 30, Exclusion Criteria: - Weight greater than 300lbs (the PET/MRI table weight limit) or BMI > 33 - Subjects less than 18 years of age or greater than 85 years of age - Has Electrical implants, such as cardiac pacemakers or perfusion pumps - Has Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, prosthetic heart valves that are not compatible with the gradient maps of our scanners, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants not compatible with a 3 Tesla MR. - Is actively anticipating being pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required on the day of the scan before the subject can participate) - Suffers from claustrophobia - If research-related radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months) - Is unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis) - Subject is under the direct professional supervision of the principal investigator - A history of chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2) - Perioperative liver transplantation period |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with a metastatic lesion noted on PET/MRI that have a true malignancy noted on surgical pathology of that lesion | Sensitivity of PET/MRI to detect metastatic lesions | Baseline | |
Primary | Percentage of patients without any metastatic lesion noted on PET/MRI that do not have malignancy noted on surgical pathology | Specificity of PET/MRI to detect abscence of metastatic lesions | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05063019 -
Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer Index
|
N/A | |
Recruiting |
NCT05597683 -
Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy
|
N/A | |
Withdrawn |
NCT04125225 -
What Are the Experiences of Patients With Pseudomyxoma Peritonei?
|
||
Completed |
NCT02189434 -
Does Serum Procalcitonin Levels Predict Sepsis in Patients Undergoing Cytoreductive Surgery
|
N/A | |
Not yet recruiting |
NCT05353582 -
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
|
Phase 2 | |
Recruiting |
NCT05939193 -
Effect of Urine-guided Hydration on Acute Kidney Injury After CRS-HIPEC
|
N/A | |
Completed |
NCT06398678 -
Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
|
||
Not yet recruiting |
NCT05633199 -
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
|
N/A | |
Completed |
NCT03646474 -
Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC
|
N/A | |
Completed |
NCT04981639 -
TAP and IMS for HIPEC
|
Phase 3 | |
Completed |
NCT04744688 -
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
|
||
Recruiting |
NCT05942209 -
ECO-LEAK Technique: Early Detection of Colorectal Anastomotic Leakage by Transvaginal Ultrasound
|